产品
编 号：F043814
分子式：C13H16N2
分子量：200.28
分子式：C13H16N2
分子量：200.28
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
25mg
400
In-stock
50mg
640
In-stock
100mg
1040
In-stock
结构图
CAS No: 113775-47-6
产品详情
生物活性：
Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects.
体内研究：
Medetomidine (10-100 μg/kg；静脉注射，间隔 5 分钟) 在戊巴比妥麻醉的大鼠中产生剂量依赖性瞳孔扩张。Animal Model:Female Sprague-Dawley rats (270-350 g)
Dosage:1, 5, 10, 50, 100 mg/kg
Administration:I.v. at 5-min intervals
Result:Produced the pupil dilatation of 2.5 mm (approximately half of the maximum effect) at the cumulative dose of 4 μg/kg.
体外研究：
Medetomidine 对大鼠脑膜中 α2 肾上腺素能受体 (Ki=1.08 nM) 的选择性高于对 α1 肾上腺素能受体 (Ki=1750 nM).Medetomidine (0.1-100 nM) 抑制场刺激小鼠输精管的抽搐反应，pD2 为 9.0。
Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects.
体内研究：
Medetomidine (10-100 μg/kg；静脉注射，间隔 5 分钟) 在戊巴比妥麻醉的大鼠中产生剂量依赖性瞳孔扩张。Animal Model:Female Sprague-Dawley rats (270-350 g)
Dosage:1, 5, 10, 50, 100 mg/kg
Administration:I.v. at 5-min intervals
Result:Produced the pupil dilatation of 2.5 mm (approximately half of the maximum effect) at the cumulative dose of 4 μg/kg.
体外研究：
Medetomidine 对大鼠脑膜中 α2 肾上腺素能受体 (Ki=1.08 nM) 的选择性高于对 α1 肾上腺素能受体 (Ki=1750 nM).Medetomidine (0.1-100 nM) 抑制场刺激小鼠输精管的抽搐反应，pD2 为 9.0。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备